DE40: Markets remain indecisive heading into the end of the week

12:00 pm 23 May 2025

  • Bayer shares gained ground after the European Medicines Agency's Committee for Medicinal Products for Human Use recommended a label extension for its Eylea 8 milligram injection solution

  • Continental shares declined following Jefferies analyst Michael Aspinall's downgrade to hold from buy, setting a price target of €80 that implies a 4.1% increase from the last price

  • Adidas shares gained after DZ Bank analyst Thomas Maul upgraded the sportswear giant to buy from hold, establishing a price target of €261 that implies a 20% increase from the last price

 

European markets closed predominantly lower on Friday, with cautious sentiment prevailing across the region as investors stepped back from the previous session's optimism. The pan-European EU50 index declined 0.27% to 5,442.6, while Germany's DE40 fell 0.29% to 24,024.6, reflecting broader concerns about economic momentum amid ongoing uncertainty over monetary policy and growth prospects.

Switzerland's SUI20 led the declines with a 0.45% drop to 12,370, while Austria's AUT20 retreated 0.23% to 4,317. France's FRA40 declined 0.16% to 7,878.4, and the Netherlands' NED25 slipped 0.10% to 933.08, with Italy's ITA40 showing resilience with only a modest 0.06% decline to 40,369.

Bucking the negative trend, Spain's SPA35 emerged as the session's standout performer, surging 1.14% to 14,302, while Poland's W20 added 0.39% to 2,800.6. The UK's UK100 managed a modest 0.09% gain to 8,755.0, supported by sector-specific strength. The VSTOXX volatility index climbed 0.82% to 18.53, reflecting heightened market uncertainty and suggesting investors are positioning for potential turbulence ahead.

 

Volatility is currently observed in the broader European market. Source: xStation

 

The German DE40 Index is retesting its previous high after making ATH yesterday, yet it remains above the 23.6% Fibonacci retracement level and the 50-day SMA—both acting as key support zones. Bulls will look to maintain momentum above recent highs to confirm the breakout, while bears may attempt to drive the index below those levels, with the 50-day SMA as a near-term target. The RSI is easing just below overbought territory, indicating a potential cooldown in bullish momentum. Meanwhile, the MACD is beginning to narrow, signaling caution as buying pressure may be losing steam. Source: xStation

 

Market News

  • Bayer shares gained ground after the European Medicines Agency's Committee for Medicinal Products for Human Use recommended a label extension for its Eylea 8 milligram injection solution; the positive opinion, based on findings from the Pulsar and Photon clinical trials, allows expanded treatment intervals of up to six months for neovascular age-related macular degeneration and diabetic macular edema, with the German pharmaceutical giant expecting a European Commission decision in the coming weeks.

  • Continental shares declined following Jefferies analyst Michael Aspinall's downgrade to hold from buy, setting a price target of €80 that implies a 4.1% increase from the last price; the downgrade comes as the German tire manufacturer showcases digital transformation initiatives at TOC Europe 2025, including its ContiConnect tire management system and TerminalMaster tire solutions aimed at sustainable port operations, with the company targeting carbon-neutral production by 2040.

  • Adidas shares gained after DZ Bank analyst Thomas Maul upgraded the sportswear giant to buy from hold, establishing a price target of €261 that implies a 20% increase from the last price; the upgrade reflects renewed confidence in the German company's strategic direction and market positioning.

  • Deutsche Bank shares moved higher as the lender proceeds with a significant risk transfer (SRT) deal linked to a $3 billion corporate loan portfolio, selling approximately $240 million in notes through its Craft program; the transaction, covering loans in North America and Europe, supports the bank's plan to reduce risk-weighted assets by €25-30 billion by year-end, with CEO Christian Sewing noting strong demand for SRT instruments despite recent market volatility.

 

Other news coming from individual DAX index companies. Source: Bloomberg Financial LP

The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.

Share:
Back

Join over 1 600 000 XTB Group Clients from around the world.